# Subthalamic beta peak power ratio as an electrophysiological marker for deep brain stimulation contact selection in Parkinson’s disease

**Authors:** Victoria D. M. Molinari, Matthias Sure, Rachel K. Spooner, Bahne H. Bahners, Alfons Schnitzler, Esther Florin, Christian J. Hartmann

PMC · DOI: 10.1186/s42466-025-00441-9 · Neurological Research and Practice · 2025-10-28

## TL;DR

This study shows that measuring beta band activity in the brain can help choose the best contacts for deep brain stimulation in Parkinson’s disease patients.

## Contribution

The study introduces beta peak power ratio as a novel electrophysiological marker for optimizing deep brain stimulation contact selection.

## Key findings

- The power ratio of the highest low beta peak ON versus OFF medication explained 23.7% of the variance in the therapeutic window.
- Beta peak measures are valuable markers for estimating optimal DBS contact selection in Parkinson’s disease patients.

## Abstract

Previous studies have demonstrated that patients with Parkinson’s disease (PD) exhibit pathologically increased beta band activity (12–35 Hz) in the basal ganglia, which peaks at an individual frequency and correlates with symptom severity. The purpose of this study was to determine whether different beta peak measures can serve as predictors for deep brain stimulation (DBS) contact selection.

Subthalamic local field potentials were acquired from 27 patients with PD (8 female, 59.0 ± 8.9 years) with (ON) and without (OFF) dopaminergic medication. Peak amplitudes and frequencies were detected in the low (12–20 Hz) and high beta band (21–35 Hz), and their predictive value for the motor symptom improvement, the therapeutic window and the optimal stimulation contact were analyzed.

In particular, the power ratio of the highest low beta peak ON versus OFF medication explained 23.7% of the variance in the therapeutic window.

Our results demonstrate that beta peak measures can serve as valuable markers to estimate contact selection to achieve an optimal DBS outcome in patients with PD.

Not applicable.

The online version contains supplementary material available at 10.1186/s42466-025-00441-9.

## Linked entities

- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Diseases:** PD (MESH:D010300)
- **Chemicals:** dopaminergic medication (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12570425/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12570425/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC12570425/full.md

---
Source: https://tomesphere.com/paper/PMC12570425